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The aim of this study was to examine the importan-
ce of psychosocial factors, such as emotional and in-
strumental social support, distress, and assumptions 
about appearance and its salience to one’s self-worth, 
and to relate these factors to depressive symptoms in 
patients with psoriasis, according to gender. A group 
of 219 patients with psoriasis, aged 18–70 years com-
pleted the Beck Depression Inventory, the Appearance 
Schemas Inventory-Revised, the Berlin Social Support 
Scales, and the Distress Thermometer. Body Surface 
Area index was used to assess the severity of psoria-
sis. The main contributors to depression were: female 
gender, beliefs about appearance and its salience to 
one’s self-worth, greater psychological distress, and 
lower levels of emotional social support. Therefore, 
improving the body image of patients with psoriasis, 
by reducing its salience in their personal lives, may 
play a role in the prevention of depression, especially 
in women.
Key words: psoriasis; depression; distress; body image; social 
support; gender.
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Psoriasis is one of the most common immune-med-iated inflammatory skin diseases, with an estima-
ted prevalence of 2–3% of the Caucasian population 
worldwide (1). Psoriasis can occur at any age and is 
equally distributed between men and women. As with 
other skin diseases, visible disfigurement triggers ne-
gative reactions in others, which can cause much of the 
readily measurable psychosocial burden of the disease. 
However, the impact of psoriasis on patients’ lives and 
well-being is often higher than in other skin and chronic 
diseases (2–4). To date, extensive literature describes the 
co-occurrence of psoriasis and depression, suicide idea-
tion, anxiety, sexual dysfunction and alcohol addiction 
(2, 5–9). Physical, psychological and socioeconomic 
burdens of psoriasis include skin discomfort, disfigura-
tion, feelings of stigmatization, and inconvenient and 
uncomfortable skin therapies. These burdens may lead 
to negative affect (in particular sadness, loneliness, and 
anger), may strongly influence body image, and may 
eventually result in negative mental health outcomes 
(10–15).
It has also been reported that women with psoriasis 
might incur a higher risk for psychological comorbidities 
than do men (14, 16–18). Thus, gender differences in the 
impact of psoriasis are an important issue. It is worth 
noting that appearance norms directed at women are 
more rigid, homogeneous, and pervasive than are those 
directed at men (19), which may exacerbate existing 
psychological distress and negative body image.
It should also be emphasized that the psychological 
impact of psoriasis may be highly individual and often 
not in proportion to the clinical severity of the disease, 
or to the extent and the location of skin lesions (9, 
20–22). In many patients, the physical psoriasis score 
may not reflect the level of psychosocial disability (9, 
23, 24). Psychological impairments in psoriasis might be 
largely attributable to patients’ perception of the disease 
(e.g. 20, 24–26) and/or beliefs about the importance of 
appearance in one’s personal life and its salience to a 
sense of self-esteem (e.g. 27–29). Furthermore, perceived 
social support and positive, acceptable experiences of 
social interactions may be of particular importance for 
this group of patients. However, social support can have 
different effects depending on the gender of the recipient 
and the match between the type of social support and 
the individual’s needs (18, 30). For example, Janowski 
et al. (18) found that social support might generally be 
more effective in preventing depression in women than 
in men with psoriasis. Less is known about the protective 
effects of different types of social support and potential 
gender differences in the links between social support 
and mental health among patients with psoriasis. Types 
of social support and gender have rarely been control-
led factors in such studies; therefore, they are important 
issues to consider.
The aims of this study were to describe the severity 
of depression and distress in patients with psoriasis in 
Poland, and to determine factors associated with depres-
sive symptoms. Selected factors, such as gender, age at 
onset of psoriasis, extent of the disease, perceived social 
support, and other psychological variables, were investi-
gated. These variables included subjective distress, and 
beliefs about the importance and influence of appearance 
in the patient’s life, which could account for increased 
probability of co-occurrence of psoriasis and depression.
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METHODS
A descriptive cross-sectional study was conducted among patients 
with psoriasis. Survey invitation letters were sent to dermatology 
outpatient and inpatient clinics, and to Polish psoriasis associa-
tions. Ethical approval was granted by the Ethics Committee of 
the University of Silesia.
Participants
Inclusion criteria were: psoriasis diagnosed by a dermatologist; at 
least one year disease duration; age ≥ 18 years; no physical disfi-
gurement unrelated to psoriasis; no serious mental or cognitive 
disturbances; and informed consent.
The final sample comprised 219 patients: 124 women (56.6%) 
and 95 men (43.4%). The baseline characteristics of the sample 
are shown in Table I.
Tools
Beck Depression Inventory (BDI). The BDI is one of the most 
widely used self-report measures of depression, with high validity 
and good psychometric properties (31, 32). The 21-item ques-
tionnaire uses a 4-point response scale (0 = low, 3 = high). Scores 
on the 21 items corresponding to the symptoms of depression are 
summed to give a single total score, ranging from 0 to 63. Higher 
total scores indicate more severe depressive symptoms. Scores 
in the range 0–13 indicate lack or minimal depression, 14–19 
mild depression, 20–28 moderate depression, and 29–63 severe 
depression. A validated Polish version of the BDI was used in the 
current study (33). Cronbach’s α coefficient for the BDI is 0.91.
Appearance Schemas Inventory – Revised (ASI-R). The ASI-R is 
a 20-item, Likert-type instrument assessing body image invest-
ment as reflected in beliefs about the importance and influence of 
appearance in one’s life (34). The ASI-R comprises 2 subscales: 
Self-Evaluative Salience (SES; 12 items), which assesses the ex-
tent to which individuals define themselves and their self-worth 
by their physical appearance, regarded as influential in their social 
and emotional experiences; and Motivational Salience (MS; 8 
items), which measures attention to appearance, and performance 
of appearance-management behaviours. In the study reported here 
the Cronbach’s α coefficient amounted to 0.88 for the general 
score, 0.89 for SES, and 0.86 for MS.
Berlin Social Support Scales (BSSS). The BSSS (35, 36) are 
multidimensional measures of social support. One of the 6 BSSS 
scales was used in the present study: Perceived Available Support 
(including perceived emotional and instrumental support). Each of 
8 items is rated on a scale from 1 (strongly disagree) to 4 (strongly 
agree). The BSSS has demonstrated good internal consistency 
and validity (35, 36). In the study reported here the Cronbach’s α 
coefficient amounted to 0.90 for the Perceived Available Support, 
0.93 for Emotional Support Subscale, and 0.88 for Instrumental 
Support Subscale.
Body Surface Area (BSA). The BSA index was used to assess the 
extent of psoriasis. BSA is a simple and commonly used instrument 
for measuring the percentage of body surface area affected by pso-
riasis (16, 37). Mild involvement of skin with psoriasis was defined 
as 1–10% BSA; moderate to severe involvement as >10% BSA (38).
Distress Thermometer (DT). The DT (39) was used to assess the 
level of distress in patients with psoriasis. The DT is a visual 
analogue scale that looks like a thermometer and ranges from 0 
(no distress) to 10 (extreme distress). Patients were instructed to 
place a horizontal line at the number corresponding to the level 
of recently experienced distress. Results of the validation study of 
the Polish version of the DT indicated that scores ≥ 4 have been 
associated with increased risk for anxiety and depressive disorders. 
Statistical analysis
Data were analysed using the statistical package STATISTICA 12 
(StatSoft Inc.). A t-test was used for group comparisons. Effect 
sizes (Cohen’s d) were also estimated and reported. Stepwise 
multiple regression analyses were used to indicate predictors of 
depressive symptoms in the total sample, and in men and in women 
separately. Multivariate logistic regression analysis was performed 
to describe factors associated with the likelihood of depression.
Table I. Demographics and clinical characteristics of the participants 
(n = 219)
Characteristics
Course of the disease, years, mean ± SD (range)
Age at onset of psoriasis 21.29 ± 12.01 (2–65)
Duration of psoriasis 16.68 ± 11.28 (1–61)
Treatment duration 13.28 ± 10.99 (0–51)
Age, years, mean ± SD (range) 38.15 ± 13.30 (18–70)
Work status, n (%)
Student 22 (10.0)
Employed 135 (61.6)
Disability pension 21 (9.6)
Retired 18 (8.2)
Unemployed 23 (10.5)
Place of residence, citizens, n (%)





< 500,000 39 (17.8)





Table II. Differences between women and men with psoriasis on depression, distress, body image, social support and extent of the disease
Characteristics of the sample
Total sample 
Mean ± SD
Women (n = 124)  
Mean ± SD
Men (n = 95) 
Mean ± SD t d
Depression 14.18 (11.41) 16.48 (12.11) 11.18 (9.68) 3.49*** 0.49
Distress 5.25 (2.88) 5.69 (2.88) 4.67 (1.06) 2.61** 0.45
BSA 13.03 (18.18) 14.03 (18.99) 11.72 (17.08) 0.93 0.13
ASI 3.47 (0.73) 3.58 (2.88) 3.33 (2.79) 2.47* 0.09
ASI-SES 3.40 (0.83) 3.52 (0.83) 3.26 (0.80) 2.32* 0.32
ASI-MS 3.57 (0.76) 3.66 (0.79) 3.45 (0.71) 2.11* 0.28
Emotional social support 12.32 (3.22) 12.19 (3.24) 12.47 (3.20) –0.64 0.09
Instrumental social support 12.47 (3.50) 12.19 (3.66) 12.85 (3.26) –1.40 0.19
*p < 0.05; **p < 0.01; ***p < 0.001.
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RESULTS
More than half of the participants (69.4%) reported 
distress score ≥ 4 on the DT. 
The mean ± standard deviation level of depressive 
symptoms, as measured by BDI (14.18 ± 11.41), were 
within the score range indicative of clinical depression 
(Table II). Almost half of the participants (49.8%) fell 
into the category of probable depression; among those, 
11.9% presented severe, 18.2% moderate and 19.7% 
mild depressive symptoms, as defined by the BDI. More-
over, nearly 21% of respondents in our sample reported 
suicidal thoughts.
Depressive symptoms and distress were significantly 
higher in women than in men (Table II). Moreover, 
women also reported more self-evaluative investment 
in their appearance, and significantly greater levels of 
motivational salience.
As Table III shows, self-evaluative salience, distress, 
emotional social support, and extent of the disease made 
significant contributions to the variance in depression in 
patients with psoriasis. The total variance of all entered 
variables was 0.49 (adjusted R2). The main contributors 
to depression were distress and emotional social support. 
Distress accounted for over 29% of the variance, and 
emotional social support accounted for a further 15% 
(Table III). The extent of the disease (BSA) accounted 
for a modest proportion of the variance, and did not 
make a significant contribution to the variance in de-
pression in women (Table III). In contrast, for women, 
the importance of appearance in their personal life and 
its salience to their sense of self emerged as a sig-
nificant predictor, contributing 5% to the variance 
in depression.
In addition, multivariate logistic regression re-
vealed that female gender was an important risk 
factor for depressive symptoms (odds ratio [OR] 
2.36). For women, the risk for depression was more 
than double that for men (Table IV). High levels 
of psychological distress (distress ≥ 4 on the DT) 
quadrupled the chances of depression in psoriasis 
patients (OR 4.17). Moreover, the importance of 
physical appearance in personal life and its salience 
to the sense of self and esteem were associated with 
a more than 4-fold increased risk of having depressive 
symptoms (OR 4.46). Analysis also revealed that emo-
tional support was the most important protective factor 
for depression (OR 0.20). The instrumental social support 
variable did not reach statistical significance.
DISCUSSION
One of our research objectives was to determine the le-
vels of psychological distress and depressive symptoms 
in Polish patients with psoriasis. Overall, and consistent 
with current knowledge, our results show high rates 
(nearly 50%) of comorbid depression in patients with 
psoriasis (2, 6, 7). High levels of psychological distress 
were present in 70% of patients. This is an important 
issue, because psychiatric disorders have been found 
to be associated with poor treatment adherence, poor 
therapeutic response, and inferior outcome in patients 
with psoriasis (40–42) and, furthermore, are an additional 
source of suffering and disability. Moreover, as recently 
reported by other authors, depression, and especially 
acute depression, in patients with psoriasis is associated 
with increased risk of myocardial infarction, stroke, and 
cardiovascular death (43).
Our results also show, consistent with what has been 
previously reported by other authors (16, 18), that 
women were more prone to depressive symptoms and 
psychological distress. Women also reported stronger 
beliefs about the importance and influence of physical 
appearance on their personal or social worth and sig-
nificantly greater levels of motivational investment in 
their appearance. Interestingly, the extent of psoriasis 
was unrelated to the risk of depression in women, and 
was a statistically significant, but weak, determinant of 
depressive symptoms in men. This result is in agreement 
with previous research (9, 16, 20, 18, 44), in which the 
severity of psoriasis was weakly or not significantly 
associated with the degree of deterioration in mental 
health and quality of life. It has also been reported (23, 
24) that physical measures of disease severity, such as 
the PASI or BSA, give only a partial indication of psy-
chosocial disability caused by psoriasis, and the impact 
of psoriasis beyond the skin often goes unrecognized or 
Table III. Predictors of depression in patients with psoriasis
Predictors













ΔR2 β ΔR2 β ΔR2 β
ASI-SES 0.04 0.21*** 0.05 0.23***
BSA 0.01 0.10* 0.03 0.19*
Emo Supp 0.15 −0.38*** 0.38 −0.45*** 0.09 −0.34***
Distress 0.29 0.34*** 0.15 0.35*** 0.21 0.38***
*p < 0.05; ***p < 0.001
ASI-SES: Self-Evaluative Salience. BSA: body surface area (extent of psoriasis); Emo 
Supp: emotional social support.
Table IV. Risk factors associated with depression in 
patients with psoriasis (n = 219)
Predictors OR 95% CI p-value
Younger onset 1.16 0.57, 2.38 0.678
Sex (female) 2.36 1.15, 4.85 0.020
BSA (> 10%) 2.47 0.73, 8.37 0.145
ASI-SES 4.46 1.40, 14.20 0.008
ASI-MS 2.00 0.72, 5.55 0.183
Emotional social support 0.20 0.07, 0.59 0.004
Instrumental social support 0.35 0.12, 1.04 0.060
Facial lesions 0.57 0.20, 1.63 0.290
Genital lesions 1.24 0.43, 3,57 0.684
Distress (≥ 4) 4.17 1.79, 9.71 < 0.001
BSA: body surface area (extent of psoriasis); ASI-SES: Self-Evaluative Salience; 
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is undertreated (45, 46). We observed, however, that the 
impact of psoriasis seems to be different in women and 
men. The results of this study suggest a direct effect of 
psoriasis on depressive symptoms in men. In contrast, 
for women the extent of the disease was unrelated to 
depression, but a significant contributor to depression 
was the importance of physical appearance in one’s 
personal life and its salience to one’s sense of self and 
esteem. Thus, our results suggest that, in women, cogni-
tive factors related to aspects of body image may serve 
as a mediator between psoriasis and negative mental 
health outcomes. However, further research is needed 
to verify this assumption.
Understanding the key risk factors of impairment may 
help physicians to identify patients who are more vul-
nerable to the negative impact of psoriasis and to make 
more appropriate treatment decisions earlier in the course 
of disease (e.g. to implement a multifaceted intervention), 
potentially preventing the progression of cumulative 
impact of the disease. The impact of psoriasis seems to 
be highly individual, and not in proportion to the severity 
of the disease (9). According to our results, a possible 
reason underlying the high prevalence of depression in 
patients with psoriasis might be an overemphasis on ap-
pearance in the evaluation of self-worth. Dysfunctional 
schematic investment in one’s appearance may strongly 
trigger disease-related burdens, especially in women. 
Psoriasis is a disease closely related to concerns about 
appearance. Moreover, women are more frequently 
valued and assessed by their appearance than are men. 
Appearance norms directed at women are also more rigid, 
homogeneous and pervasive than are those for men (19). 
Therefore, women with a greater self-evaluative salience 
of their appearance might be particularly predisposed 
to body image dissatisfaction, which may exacerbate 
psychological distress, and consequently increase risk of 
depression. In contrast, in men, self-evaluative salience 
of appearance did not seem to play a role in depressive 
symptoms. However, we detected other risk factors for 
depression in both genders. Psychological distress was 
an important risk factor for depression both in men and 
in women. This result is in line with a previous report 
(22), suggesting that patients with high subjective dist-
ress, regardless of disease severity, should be evaluated 
for depression.
Moreover, according to our results, higher levels of 
perceived emotional social support were positively linked 
to lower depressive symptoms. Emotional support was 
the most important protective factor for depression in 
psoriasis patients; however, this relationship was con-
siderably more significant in women. But, contrary to 
our expectations, there was no significant association 
between instrumental social support and depression. We 
hypothesize that the role of instrumental social support 
may be more complex, because this type of support 
may make patients feel less in control of their situation, 
decrease the controllability of the disease and enhance 
helplessness. There is little evidence for a mental health 
benefit from the various types of social support to patients 
with psoriasis. However, Janowski et al. (18) reported 
that higher tangible support was the strongest predictor 
of lower depressive symptoms in patients with psoriasis, 
and that other social support dimensions did not reach 
significance. In line with our outcomes, they stated that 
social support may be viewed as a buffer for emotional 
disturbances revealed in the form of depressive symp-
tomatology in women, whereas this effect may be less 
important for men. Further research is needed before 
strong conclusions can be made regarding the protective 
effects of various social supports on mental health in 
patients with psoriasis.
As mentioned earlier, in this study, clinical charac-
teristics of psoriasis, such as extent of the disease, had 
poor predictive value for depression. Localization of 
skin lesions and clinical history variables, such as age at 
onset, did not reach statistical significance. In contrast, 
Remröd et al. (47) found that patients with early-onset 
psoriasis (age < 20 years) were significantly more de-
pressed and anxious than were patients with late onset 
of the disease. However, there is still little information 
available on the link between childhood onset of psoriasis 
and mental health in adulthood. Early-onset psoriasis 
has the potential to change the patient’s life trajectory 
substantially (15, 48) and may be an important, but 
not essential, risk factor for depression in patients with 
psoriasis. Moreover, our results might best be viewed 
in light of the cognitive-behavioural importance of ap-
pearance in one’s personal life. In this study, 72.1% of 
participants were between 18 and 45 years old; therefore, 
it is safe to assume that their beliefs and attitudes toward 
the body are the result of cultural changes that have oc-
curred in the past 5–10 years, especially a societal focus 
on beauty and the notion of the “perfect body”, as is 
often conveyed in modern mass media. Accordingly, our 
results indicate that maladaptive beliefs about physical 
appearance and its salience to one’s life and self-worth 
are important risk factors for depression (especially in 
women). However, this relationship may be considera-
bly more complex than it first appears. Paradoxically, in 
patients with severe psoriasis, a more severe condition 
may have the effect of reducing their investment in ap-
pearance and its salience to their lives. Patients with more 
severe disease may feel exempt from societal standards 
and cultural expectations of the perfect body, and may be 
able to develop consistent and effective ways of coping. 
In contrast, individuals with mild skin lesions may be 
more likely to feel pressured to meet ideals of physical 
appearance, and, among these individuals, body image 
investment reflected in beliefs about the importance of 
appearance in one’s life and self-worth can be a major 
contributor to negative mental health outcomes. Thus, 
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may be largely attributable to patients’ maladaptive as-
sumptions about physical appearance and society’s focus 
on beauty and the perfect body, rather than to the age of 
onset of psoriasis. Further research is are needed to test 
these assumptions.
In our study, the presence of psoriatic lesions on the 
face or genital skin did not have a significant association 
with depressive symptoms. These results are contrary 
to previous research (22), where the presence of genital 
lesions was clearly linked to depression. Nevertheless, 
other authors have suggested that the psychological bur-
den of psoriasis might be largely attributable to the mere 
fact of having psoriasis and the patient’s own perception 
of the disease and/or other psychological factors, rather 
than to physical characteristics of psoriasis, such as se-
verity, localization of skin lesions, and clinical history 
variables, such as family history, duration, and age at 
onset (18, 20, 49). For example, Hrechorów et al. (49) 
found that the presence of psoriatic lesions on the face 
had no influence on patients’ feelings of stigmatization, 
even though patients with facial lesions had significantly 
more severe psoriasis and the face is the most visible area 
of the body. Future studies should pay more attention to 
the associations between depression and the presence 
of psoriatic lesions on readily visible and “emotionally 
charged” body regions, such as face, hands, and/or ge-
nitals, vs. body areas that can be covered more easily. In 
addition, further research is required to better determine 
the link between childhood onset of psoriasis and mental 
health in adulthood.
Strengths and limitations
To our knowledge, this is the first study to evaluate the 
role of psoriasis patients’ assumptions about physical 
appearance and its salience to their life and self-worth 
as a risk factor for depression. However, this study has 
some limitations that should be taken into consideration 
when interpreting the results. First, our sample included 
participants from psoriasis associations, which may li-
mit the generalizability of the results. Members of such 
associations may have (by the very fact of their mem-
bership) considerable concern regarding their disease 
and, possibly, greater psychosocial burden of psoriasis. 
Secondly, the study was cross-sectional in nature, and so 
has all the disadvantages of cross-sectional studies (e.g. 
one cannot determine the sequence of events). Therefore, 
prospective replication is necessary to confirm the results. 
Thirdly, as in previous studies (16, 22, 37), the extent of 
psoriasis was assessed according to BSA. This measure 
enables one to define the body surface area affected by 
psoriasis, but is not a complete assessment of severity. 
BSA does not estimate other clinical signs, such as er-
ythema, induration, and desquamation. Future research 
could extend the current findings by taking into account 
the assessment of psoriasis severity measured both by 
the physician and by the patient’s self-report.
Moreover, our results showed, consistent with oth-
ers’ reports (18), that women with psoriasis were more 
prone to depressive symptoms than were men. National 
population surveys have also consistently shown a hig-
her prevalence of depression in women than men (50, 
51). However, gender is likely to play an important role 
in how men and women conceptualize and experience 
depression (52, 53). The large gap in depression rates 
between men and women may be strongly affected by 
individuals’ adherence to socially constructed gender role 
norms. Women may see depression as a socially accepta-
ble reaction to visible disfigurement and be more likely 
than men to endorse the internalizing symptoms that are 
consistent with standard DSM-5 diagnostic criteria. Men 
may be more likely than women to manifest externali-
zing symptoms (e.g. irritability, aggression, substance/
alcohol abuse) not included in a standard evaluation for 
a depressive disorder. Therefore, the higher prevalence 
of depression in women may be an artefactual finding. 
According to Martin et al. (52) and Genuchi & Mitsu-
naga (53), when externalizing symptoms are included in 
the assessment of depression, the gender differences in 
overall symptoms disappear. Thus, further research is ne-
cessary, using a measure that includes both internalizing 
and externalizing depressive symptoms, to understand 
gender differences in the co-occurrence of psoriasis and 
depression.
Conclusion
High rates of psychological impairments were found in 
patients with psoriasis in Poland. The results indicate the 
importance of early diagnosis of psychological burden 
of the disease and a great need for more comprehensive 
management. Clinicians should increase their awareness 
of the broad impact of psoriasis on patients’ lives and 
the importance of psychosocial factors, such as body 
image and social emotional support, in the course of 
the disease. It is worth noting that the psychological 
impact of psoriasis is not in proportion to the severity 
of the disease. To understand the relationship between 
psoriasis and depression, one must take into account 
the patient’s subjective distress and the role of general 
societal pressure to achieve an ideal appearance, as well 
as the perceived importance of physical appearance in 
gaining societal worth and acceptance.
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